

Tuesday 25 August 2026

NeuroStrip secures UK registration, accelerating commercial expansion with early trials underway

Control Bionics Limited (ASX: CBL) today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has registered its wearable surface electromyography device, NeuroStrip, clearing the primary regulatory hurdle for commercial supply in Great Britain.

MHRA registration confirms Control Bionics' status as a registered medical device manufacturer and enables the Company to pursue commercial supply and revenue generation across England, Scotland and Wales.

The UK offers a well-established and well-funded rehabilitation and research sector, alongside elite sports markets, all of which represent potential applications for NeuroStrip.

Three pilot programs demonstrating the device's clinical and performance value are already underway, with several additional customer trials due to start in September 2026. Initial customers include Dr. Tom Maden-Wilkinson (University of Lancaster and University of Sheffield) – a world leading expert in sEMG and the University of Nottingham and British Olympics. Feedback from these users will be a core component of the Company's sales-conversion strategy and will inform its UK market-entry approach, as well as broader expansion across Europe.

Control Bionics CEO and Managing Director Jeremy Steele said: "UK registration is another milestone in our ongoing global commercial expansion. The UK is a key commercial market for NeuroStrip, and we are moving quickly from regulatory clearance to commercial execution.

"Combined with our US FDA registration, we are building the foundations to scale NeuroStrip across major international markets."

NeuroStrip is registered in the Global Medical Device Nomenclature (GMDN) under code 63697 and classified as a psychophysiological biofeedback system.

This announcement has been authorised for release to the ASX by the Board of Control Bionics Limited.

Jeremy Steele
CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley
Company Secretary
brettcrowley@controlbionics.com

About Control Bionics

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes. A single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications. Control Bionics' technology does not require surgery or implantation, and holds regulatory clearances in the US, Australia and Europe. The Company is also a registered NDIS provider in Australia.